pneumococci
Conditions
Interventions
Sponsors
London School of Hygiene and Tropical Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Resident in the study area
Exclusion criteria
Exclusion criteria: Intent to move out of the study area before 4 months of age. Age greater than 9 months Completed PCV schedule Contraindication to PCV13 – severe hypersensitivity to a previous dose of PCV13
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasopharyngeal (NP) carriage of vaccine-type (VT) pneumococci in children aged 2 weeks - 59 months with clinical pneumonia. | — |
Secondary
| Measure | Time frame |
|---|---|
| .NP carriage of non-vaccine-type (NVT) pneumococci in children aged 2 weeks - 59 months with clinical pneumonia. • Population-based NP prevalence of VT and NVT pneumococci with measurement of interpersonal contact patterns. • NP prevalence of VT and NVT pneumococci in infants presenting for the first dose of PCV aged 6 – 12 weeks. • Incidence of radiological pneumonia in children aged 2 weeks - 59 months. • Incidence of clinical pneumonia in children aged 2 weeks - 59 months. • Incidence of clinical pneumonia with NP carriage of VT pneumococci in children aged 2 weeks – 59 months • Incidence of serotype-specific IPD in children aged 2 weeks - 59 months. • Incidence of hospitalisation in children aged 2 weeks – 59 months. • Mortality in children aged 2 weeks - 59 months. | — |
Countries
Gambia
Contacts
Public ContactJama Jack
Head of Communications MRCG at LSHTM
Outcome results
None listed